BioAlliance Pharma in-licenses new pipeline project


Paris – BioAlliancePharma has filled its early-stage pipeline with Odansentron. The 5-HT3 compound is already marketed as a tablet, and now BioAlliance is planning to develop it as a mouth spray. “This fits well into our strategy to expand our presence in supportive care for oncology patients, and to focus on patient convenience,” company CEO Dominique Constantini told EuroBiotechNews. BioAlliance paid US$3m for the European rights for the Odansentron spray in advance to US-based NovaDel Pharma Inc. The out-licensor is also eligible for milestones potentially amounting to US$24m. Bio­Alliance’s responsibility will be to bring the product to market in Europe. In the US, NovaDel’s partner Par Pharmaceutical is responsible for the clinical development and the US registration. BioAlliance will use these documents for the European application. Par and BioAlliance are already cooperating on Loramyc, which is a novel miconazole lozenge-formulation against oral candidiasis.
The Euronext-listed BioAlliance focuses on specialty pharma products sold in the hospital. The company launched Loramyc last year in cooperation with Dutch Spe-pharm in Europe. Bio­Alliance is running two Phase III trials with Acyclovir, a tablet against labial herpes, and with a new formulation of Doxorubicin. To overcome resistance issues, the approved chemotherapeutic was formulated with nanoparticles and masked by sugar residues. BioAlliance pharma has EUR56m in the bank, and is currently burning almost EUR20m per year. In 2012, the company aims to have four products on the market.



Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...



Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...



Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...



Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...



Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...



Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...



Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance


Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance


Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Stock list

All quotes


  • PROTHENA PLC (IE)68.70 USD9.45%
  • HYBRIGENICS (F)1.63 EUR9.40%
  • PHARMING (NL)0.34 EUR6.25%


  • SERODUS (N)2.60 NOK-15.58%
  • ZELTIA (E)3.69 EUR-8.44%
  • IXICO (UK)33.00 GBP-7.04%


  • DBV TECHNOLOGIES (F)77.15 EUR48.4%
  • IXICO (UK)33.00 GBP46.7%
  • ADOCIA (F)90.05 EUR40.7%


  • BIOTEST (D)25.67 EUR-63.3%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%


  • ADOCIA (F)90.05 EUR543.7%
  • FORMYCON (D)27.30 EUR298.5%
  • PROTHENA PLC (IE)68.70 USD295.5%


  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEOVACS (F)1.05 EUR-70.1%
  • BIOTEST (D)25.67 EUR-68.7%

No liability assumed, Date: 28.07.2015

Current issue

All issues